Shawn Malone, MD
Neoadjuvant and concurrent androgen-deprivation therapy (ADT) with dose-escalated prostate radiotherapy (PRT) and concurrent and adjuvant ADT plus dose-escalated PRT were found to have no statistically significant differences in biochemical relapse-free survival (bRFS) in patients with localized prostate cancer, according to results of a phase III trial.
“Our study raises the possibility of a modest improvement in biochemical or clinical relapse with concomitant and adjuvant ADT rather than neoadjuvant and concurrent ADT combined with dose-escalated PRT in [localized prostate cancer],” Malone and coinvestigators wrote. “This difference, however, did not reach statistical significance, possibly because of a lower-than-anticipated event rate with a corresponding loss of statistical power…these results demonstrate encouraging long-term oncologic outcomes with the combination of short-term ADT and dose-escalated RT in intermediate-risk [prostate cancer]. The results of our study support flexibility in tailoring the sequence of ADT and RT to optimize treatment adherence and convenience for patients with [localized prostate cancer].”
Malone S, Roy S, Eapen L, et al. Sequencing of androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: a phase III randomized controlled trial. J Clin Oncol. 2019;38(6):593-610. doi: 10.1200/JCO.19.01904.
... to read the full story